Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

SGLT2 Inhibitors and Potential Applications in Treating Metabolic Syndrome

Version 1 : Received: 15 April 2022 / Approved: 21 April 2022 / Online: 21 April 2022 (10:12:04 CEST)

How to cite: Goddard, C.; Allenspach, K.; Deflandre, A.; Zemirline, C.; Guillot, E.; Mochel, J.P. SGLT2 Inhibitors and Potential Applications in Treating Metabolic Syndrome. Preprints 2022, 2022040202. https://doi.org/10.20944/preprints202204.0202.v1 Goddard, C.; Allenspach, K.; Deflandre, A.; Zemirline, C.; Guillot, E.; Mochel, J.P. SGLT2 Inhibitors and Potential Applications in Treating Metabolic Syndrome. Preprints 2022, 2022040202. https://doi.org/10.20944/preprints202204.0202.v1

Abstract

SGLT2 inhibitors act to induce glucosuria and have been shown to be efficacious in the treatment of type II diabetes mellitus but have also been shown to positively affect cardiovascular conditions and some benefitting kidney function. SGLT2i have shown to be effective in more advanced conditions but may eventually be a treatment in more general metabolic dysfunction. Metabolic syndrome is a clinical diagnosis for establishing risk for ischemic heart disease and diabetes. The prevalence of type II diabetes mellitus, heart disease, and severe vascular events steadily increased over recent decades. In addition to the established benefits of diet and exercise, SGLT2 inhibitor therapy may be able to aid in the treatment of metabolic syndrome from its proven cardiovascular and anti-hyperglycemic benefits. Pharmacologic modeling in canines is also considered, as they present with similar diagnoses and offer a model that shares many of the characteristics of humans in metabolic dysfunction.

Keywords

Metabolic syndrome; SGLT2 inhibitors; Dapagliflozin; Empagliflozin; Canagliflozin; Translational modeling

Subject

Medicine and Pharmacology, Endocrinology and Metabolism

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.